Certara Inc. (CERT) News

Certara Inc. (CERT): $16.73

0.20 (+1.21%)

POWR Rating

Component Grades

Momentum

D

Stability

B

Sentiment

Quality

C

Add CERT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#117 of 357

in industry

Filter CERT News Items

CERT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CERT News Highlights

  • CERT's 30 day story count now stands at 2.
  • Over the past 22 days, the trend for CERT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DRUG, CMC and DE are the most mentioned tickers in articles about CERT.

Latest CERT News From Around the Web

Below are the latest news stories about CERTARA INC that investors may wish to consider to help them evaluate CERT as an investment opportunity.

Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies

Combined organization establishes the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence contributing to faster and more effective medicine development.PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) today announced it has acquired Applied BioMath, an industry-leader in providing model-informed drug discovery and development support to help accelerate and de-risk therapeutic research and development (R&D). Together, Certa

Yahoo | December 13, 2023

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapiesPRINCETON, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed for use by biopharmaceutic, formulation, and CMC scientists to aid in formulating complex novel and generic small molecule medicines quickly and cost effective

Yahoo | November 21, 2023

Certara, Inc. (NASDAQ:CERT) Q3 2023 Earnings Call Transcript

Certara, Inc. (NASDAQ:CERT) Q3 2023 Earnings Call Transcript November 8, 2023 Certara, Inc. reports earnings inline with expectations. Reported EPS is $0.11 EPS, expectations were $0.11. Operator: Good day, and thank you for standing by. Welcome to the Certara Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being […]

Yahoo | November 10, 2023

Q3 2023 Certara Inc Earnings Call

Q3 2023 Certara Inc Earnings Call

Yahoo | November 9, 2023

Certara, Inc. (CERT) Q3 Earnings Meet Estimates

Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2023

Certara Reports Third Quarter 2023 Financial Results

Reiterates Full Year 2023 Financial GuidancePRINCETON, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023. Third Quarter Highlights: Revenue was $85.6 million, compared to $84.7 million in the third quarter of 2022, representing growth of 1% over the third quarter of 2022. Broad based recovery in services bookings during the quarter. Net loss was $49.0 million, comp

Yahoo | November 8, 2023

Top 12 Medical AI Companies

In this article, we will take a look at the top 12 medical AI companies. To see more such companies, go directly to Top 5 Medical AI Companies. The healthcare and medical industry is one of the biggest beneficiaries of the AI boom. Over the past few years and months there has been a surge in […]

Yahoo | October 31, 2023

Are Options Traders Betting on a Big Move in Certara (CERT) Stock?

Investors need to pay close attention to Certara (CERT) stock based on the movements in the options market lately.

Yahoo | October 20, 2023

Are Certara, Inc.'s (NASDAQ:CERT) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Certara (NASDAQ:CERT) has had a rough three months with its share price down 29%. However, the company's fundamentals...

Yahoo | October 17, 2023

Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference

PRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 after the market close on Wednesday November 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certar

Yahoo | October 11, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!